Skip to content

Soft Mist Spray Device for Airway Anaesthesia During Awake Videolaryngoscopy

Soft Mist Spray Device for Airway Anaesthesia During Awake Videolaryngoscopy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05478122
Acronym
CT2Trachospray
Enrollment
20
Registered
2022-07-28
Start date
2022-07-25
Completion date
2023-02-11
Last updated
2023-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Airway, Anesthesia, Local

Brief summary

Rationale: Effective and fast topical anaesthesia of the upper airway is of paramount importance in awake (conscious) videolaryngoscopy of the airway in order to avoid patient discomfort. Different methods of anesthetizing the airway have been described. Conventional topical airway anaesthesia is not always effective due to non-optimal flow patterns and generation of ineffective local anaesthetic aerosols. Other methods of anaesthetizing the airway are more invasive. In order to optimize topical anaesthesia of the airway a soft mist spray device (Trachospray) for topical anaesthesia of the airway has been developed, in which optimal airflow patterns are obtained and local anaesthetic aerosols are generated which will reach the target zone for anesthetizing the airway. Objective: In this study, the Trachospray will be used for awake videolaryngoscopy, to evaluate its use, effectiveness and comfort level for patients and anaesthesiologist. Study design: Interventional study. Study population: 20 healthy human volunteers, ASA 1, 18-60 years old. Intervention: Subjects will be asked to inhale 4 ml lidocaine 4% via the Trachospray device Main study parameters/endpoints: Anaesthesia of the airway as evaluated with successful awake videolaryngoscopy with minimal discomfort for the subject. Nature and extent of the burden and risks associated with participation: Risk management on the Trachospray device shows that all user risks are mitigated and no residual risks remain for the use of the device. Testing of the device and the application of the device in daily practice has no additional risks than the present technique of performing anaesthesia of the airways.There may be some discomfort during the procedure, mainly airway irritation which may cause coughing or gag reflex.

Interventions

DEVICETrachospray for awake videolaryngoscopy

Subjects will be asked to inhale 4 ml lidocaine 4% via the Trachospray device

Sponsors

Radboud University Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Age between 18-60 years * Lean body weight \>= 50 kg * ASA physical status 1

Exclusion criteria

* Inability to cooperate with adequate airway assessment, * History of hepatic, renal and coagulation diseases, * Respiratory tract pathology * Pregnancy * Risk of regurgitation or aspiration * Allergy to amide type of local anaesthetics * No written informed consent by subject

Design outcomes

Primary

MeasureTime frameDescription
Complete anaesthesia of the airway as evaluated with successful awake videolaryngoscopy with minimal discomfort for the subject3 monthsDiscomfort and level of anesthesia will be measured with a numerical rating scale (NRS). 60 / 5.000 Vertaalresultaten So the result will be displayed in whole numbers.

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026